Genetic testing company 23andMe has filed for Chapter 11 bankruptcy to facilitate a sale, leaving its 15 million customers wondering about the future of their genetic data. The move comes amid concerns over privacy and potential misuse of sensitive genetic information.
Despite the bankruptcy filing, 23andMe claims it will continue to handle user data in accordance with laws governing customer information. However, experts warn that any buyer must comply with similar regulations or risk facing regulatory scrutiny.
Genetic data holds significant value for corporations and researchers alike, offering insights into health predispositions, food preferences, and more. Experts say the data could be used to personalize products, medical research, and even advertising.
One potential use of genetic data is discovering health predispositions, which 23andMe offers through a subscription service. This type of data also has applications in healthcare research and developing personalized medicine.
However, concerns over genetic discrimination persist. While the Genetic Information Nondiscrimination Act protects genetic information from being used for insurance or employment purposes, there are limited regulations in place to prevent its misuse elsewhere.
A 23andMe sale would be the latest example of a genetic testing firm changing hands. The company’s data remains valuable even after a change in ownership, raising questions about potential misuses.
Experts caution that genetic data can be used to exploit consumers, who may not be aware of how their information is being used. As one expert noted, “Genetic data is permanent and unique,” making it a sensitive topic that requires careful handling.
Source: https://edition.cnn.com/2025/03/30/business/23andme-for-sale-genetic-data/index.html